Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Globalization Capacity, Shortage Monitoring Remain Concerns, GAO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

In updated high-risk report, GAO says resources are an issue for FDA’s globalization plans and the agency should better manage its drug shortage data.

Advertisement

Related Content

FDA Mutual Reliance with EU on Inspections Is Slow Going
FDA Mutual Reliance With EU On Inspections Is Slow Going
Updated: FDA Manufacturing Inspectors Could Be Further Divided Into Subspecialties
FDA Field Operations Would Endure Reductions Under Budget
Drug Shortage Analysis Puts FDA At Loggerheads With GAO
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections
FDA To Close Office In Amman, Jordan; Operations Moving To White Oak
FDA Could Release GMP Data To Prod Manufacturing Improvements
Generic Rx Shortage Initiative Stuck: Too Few Manufacturers To Pick Up Slack
FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS078143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel